At the news
? NEUTRALIMPACT 2/10 8-K filed Nov 9, 2026 at 07:28 ET
Ocular Therapeutix elected Riad Sherif, M.D. to its board effective November 6, 2026, and received notice that director Seung Suh Hong, Ph.D. will resign effective December 31, 2026. Dr. Hong's resignation is stated as not due to any disagreement with the board or management. This is a routine board composition change with no material financial impact.
- Riad Sherif, M.D. elected to the board as a Class I member, effective November 6, 2026
- Dr. Sherif is CEO of Oculis Holding AG and has prior experience at Novartis, Alcon, and Sanofi
- Dr. Sherif received an option for 88,000 shares at $6.60/share and an RSU award for 28,000 shares, both vesting annually over three years
- Seung Suh Hong, Ph.D. notified the company of his resignation from the board, effective December 31, 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access